Sage Therapeutics, Inc. (SAGE) NASDAQ

8.68

+0(+0.00%)

Updated at July 31 04:00PM

Currency In USD

Sage Therapeutics, Inc.

Address

215 First Street

Cambridge, MA 02142

United States of America

Phone

617 299 8380

Sector

Healthcare

Industry

Biotechnology

Employees

353

First IPO Date

July 18, 2014

Key Executives

NameTitlePayYear Born
Mr. Barry E. GreenePresident, Chief Executive Officer & Director1.28M1963
Mr. Gregory ShifermanSenior Vice President, General Counsel & Secretary617,345N/A
Mr. Christopher BenecchiChief Operating Officer & Treasurer757,8001972
Dr. Helen ColquhounSenior Vice President of Drug Safety & Pharmacovigilance0N/A
Dr. Aaron Koenig M.D.Medical Director of Early Clinical Development0N/A
Mr. Michael Quirk Ph.D.Chief Scientific Officer & Interim Head of R&D0N/A
Ashley KaplowitzDirector of Investor Relations0N/A
Ms. Vanessa ProcterSenior Vice President of Corporate Affairs0N/A
Mr. Jeff BoyleInvestor Contact0N/A
Ms. Pamela HerbsterVice President & Head of People0N/A

Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.